The state of innovation in drug development

被引：192

作者：

Kola, I. ^{[1
]}

机构：

[1] Schering Plough Corp, Kenilworth, NJ 07033 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷 / 02期

关键词：

D O I：

10.1038/sj.clpt.6100479

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The pharmaceutical industry is facing tremendous pressure, not only from payers but as a result of public perception, regulatory hurdles, and the intricacies of research and development (R&D). The latter two are significant in that they affect the number of drugs that may be registered by regulatory authorities, the time to discover and develop drugs, and the cost of drug development. Because drug development has been stagnant in terms of innovation, there exists huge potential for innovation. Failure to innovate drug development will render the "big pharma" model unsustainable.

引用

页码：227 / 230

页数：5

共 11 条

[1] A role for fMRI in optimizing CNS drug development [J].

Borsook, D ;

Becerra, L ;

Hargreaves, R .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (05) :411-424

[2]

ELIAS T, 2006, IN VIVO, V24, P49

[3] Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes [J].

Herman, Gary A. ;

Bergman, Arthur ;

Stevens, Catherine ;

Kotey, Paul ;

Yi, Bingming ;

Zhao, Peng ;

Dietrich, Bruno ;

Golor, George ;

Schrodter, Andreas ;

Keymeulen, Bart ;

Lasseter, Kenneth C. ;

Kipnes, Mark S. ;

Snyder, Karen ;

Hilliard, Deborah ;

Tanen, Michael ;

Cilissen, Caroline ;

De Smet, Marina ;

de Lepeleire, Inge ;

Van Dyck, Kristien ;

Wang, Amy Q. ;

Zeng, Wei ;

Davies, Michael J. ;

Tanaka, Wesley ;

Holst, Jens J. ;

Deacon, Carolyn F. ;

Gottesdiener, Keith M. ;

Wagner, John A. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) :4612-4619

[4] Can the pharmaceutical industry reduce attrition rates? [J].

Kola, I ;

Landis, J .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :711-715

[5] Pharmacogenetics - where are we and where are we heading? [J].

Kola, I .

PHARMACOGENOMICS, 2005, 6 (08) :793-795

[6] Innovation and greater probability of success in drug discovery and development - from target to biomarkers [J].

Kola, I ;

Hazuda, D .

CURRENT OPINION IN BIOTECHNOLOGY, 2005, 16 (06) :644-646

[7]

Mullin R, 2003, CHEM ENG NEWS, V81, P8, DOI 10.1021/cen-v081n019.p008a

[8]

Owens J, 2007, NAT REV DRUG DISCOV, V6, P99, DOI 10.1038/nrd2247

[9] The bitterest pill [J].

Pearson, Helen .

NATURE, 2006, 444 (7119) :532-533

[10]

U. S. Food and Drug Administration, 2004, INN STAGN CHALL OPP

← 1 2 →